Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 17, 2017 - Issue 5
Submit an article Journal homepage
236
Views
5
CrossRef citations to date
0
Altmetric
Original Research

The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use

Hiroji UemuraDepartment of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, JapanView further author information
,
Marco DiBonaventuraKantar Health, New York, NY, USA​​View further author information
,
Ed WangUS HEOR, Bayer HealthCare, Whippany, NJ, USAView further author information
,
Dianne Athene LedesmaMarket Access, Bayer Yakuhin, Ltd., Osaka, JapanView further author information
,
Kristen ConcialdiKantar Health, New York, NY, USA​​View further author information
&
Yasuko AitokuMarket Access, Bayer Yakuhin, Ltd., Osaka, JapanCorrespondence[email protected]
View further author information
Pages 511-517 | Received 18 Jan 2017, Accepted 24 Feb 2017, Published online: 10 Mar 2017

References

  • Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–1192. ​​
  • Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148–1159.
  • European Association of Urology [Internet]. EAU guidelines on prostate cancer. [ cited 2017 Feb 18]. Available from: https://uroweb.org/individual-guidelines/oncology-guidelines/
  • Akaza H. Current status and future direction of the treatment of CRPC (castration-resistant prostate cancer). Nihon Rinsho. 2014;72:2108–2115.
  • Crawford ED, Higano CS, Shore ND, et al. Treating patients with metastatic castration-resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537–1547.
  • Schmid S, Omlin A, Blum D, et al. Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer – going beyond PSA and imaging, a systematic literature review. Ann Oncol. 2015;26:2221–2247.
  • Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
  • M3 Global Research [Internet]. [ cited 2016 Dec 1]. Available from: http://research.m3.com/
  • Anterio Inc [Internet]. [ cited 2016 Dec 1]. Available from: http://www.anterio.co.jp/
  • Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer. Ann Oncol. 2015;26:368–374.
  • Sternberg CN, Baskin-Bey ES, Watson M, et al. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC Urol. 2013;13:58.
  • Engel-Nitz NM, Alemayehu B, Parry D, et al. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US-managed care population. Cancer Manag Res. 2011;3:233–245.
  • Flaig TW, Potluri RC, Ng Y, et al. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5:182–191.
  • Malangone E, Foley KA, Wilson K, et al. Treatment sequencing patterns of novel agents in patients with prostate cancer. J Clin Oncol. 2014;32:296.
  • Sorensen S, Ellis L, Wu Y, et al. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Managed Care Pharm. 2013;19:799–808.
  • Pilon D, Queener M, Lefebvre P, et al. Cost per median overall survival month associated with abiraterone acetate and ensalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ. 2016;19:777–784.
  • National Comprehensive Cancer Network [Internet]. NCCN clinical practice guidelines in oncology: prostate cancer (version 3.2016). [ cited 2016 Dec 1]. Available from: http://www.tri-kobe.org/nccn/guideline/urological/english/prostate.pdf
  • Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol. 2015;12:340–356.
  • Nørgaard M, Jenson AO, Jacobsen JB, et al. Skeletal-related events, bone metastasis and survival of prostate cancer: a population-based cohort study in Denmark (1999–2007). J Urol. 2010;184:162–167.
  • Howard LE, De Hoedt AM, Aronson WJ, et al. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis. 2016;19:380–384.
  • Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl. 2013;15:342–349.
  • Penson DF, Lin DW, Karsh L, et al. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016;12:2689–2699.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.